Biogen Inc (BIIB) Q1 2026 Earnings Call Transcript
Biogen reported $2.8 billion revenue for Q1 2026, a 7% increase driven by four new launch products and resilient U.S. multiple‑sclerosis sales. Non‑GAAP diluted EPS rose 4% to $5.25, and the company lifted its 2025 EPS guidance to $15.50‑$16 while keeping revenue flat year‑over‑year. The quarter featured strong commercial momentum for LEQEMBI, SKYCLARYS and ZURZUVAE, alongside a $1.75 billion debt refinancing and progress on late‑stage pipeline assets such as felzartamab and salanersen. Management highlighted the Fit for Growth initiative delivering $1 billion in gross savings and underscored upcoming regulatory milestones, including the LEQEMBI subcutaneous PDUFA in August 2025.
Agios Pharmaceuticals Inc (AGIO) Q1 2026 Earnings Call Transcript
Agios Pharmaceuticals reported a 45% year‑over‑year jump in PYRUKYND net revenue to $12.5 million, driven by stronger PKD sales, an extra ordering week, and higher specialty‑pharmacy processing. The company ends the quarter with roughly $1.3 billion in cash, supporting both commercial rollout...
Adeno-Associated Virus-Based Approaches for Mitochondrial Diseases: Advances and Challenges
Adeno‑associated virus (AAV) vectors are emerging as a versatile platform for treating mitochondrial diseases, especially those caused by nuclear‑encoded gene defects. Pre‑clinical studies have shown that AAV‑mediated delivery of nuclear genes can restore oxidative phosphorylation, extend survival, and improve organ...
Safety and Efficacy of Intratumoural Anti-CTLA4 with Intravenous Anti-PD1
The phase 1b NIVIPIT trial compared intratumoural (IT) ipilimumab at 0.3 mg kg⁻¹ plus intravenous nivolumab with the standard intravenous (IV) ipilimumab‑nivolumab regimen in untreated advanced melanoma. The IT arm achieved a markedly lower rate of grade 3‑4 treatment‑related adverse events (24 % vs 67 %...
Ionis Pharmaceuticals Inc (IONS) Q1 2026 Earnings Call Transcript
Ionis Pharmaceuticals reported record 2025 revenue of $944 million, a 34% year‑over‑year increase driven by strong sales of TRYNGOLZA, the launch of DAWNZERA, and robust R&D collaboration fees. Phase III data for olezarsen demonstrated up to a 72% reduction in triglycerides and...
Urban Edge Properties (UE) Q1 2026 Earnings Call Transcript
Urban Edge Properties reported Q1 2026 net revenue of $12.5 million, a 45% year‑over‑year increase driven by stronger PKD sales, an extra ordering week, and expanded specialty pharmacy distribution. Patient enrollment rose to 248 completed forms with 142 patients now on...
Regeneron Pharmaceuticals Inc (REGN) Q1 2026 Earnings Call Transcript
Regeneron reported Q1 2025 revenue of $3 billion, with Dupixent and Libtayo delivering double‑digit growth while U.S. EYLEA sales fell 39% to $736 million amid co‑pay assistance gaps and rising Avastin use. Gross margin guidance was revised to 86‑87% after larger‑than‑expected inventory...
Anika Therapeutics Inc (ANIK) Q1 2026 Earnings Call Transcript
Anika Therapeutics posted total revenue of $28.2 million for the quarter, an 8% decline driven by manufacturing yield issues and a $900,000 shortfall in international osteoarthritis‑pain sales. Gross margin fell to 51%—down 16 percentage points—after a one‑time $3 million non‑cash charge, though...
The BioPharm Brief: Expanding Access and Redefining Cancer Treatment
Henlius and Organon received European Commission approval for a pertuzumab biosimilar, expanding HER2‑targeted therapy access across the EU. Pfizer announced Phase 3 data showing its bispecific antibody Elrexfio improves progression‑free survival in relapsed or refractory multiple myeloma. Genexine disclosed pre‑clinical activity...
STAT+: AIDS Group Sues Trump Administration over Undisclosed Agreement with Gilead
An AIDS activist group has sued the Trump administration for failing to disclose a research and development agreement that underpinned a 2025 settlement with Gilead Sciences over patents on HIV‑prevention drugs Truvada and Descovy. The settlement ended a lawsuit dating...
Hospitals, Insurers Clash on 340B Rebate Costs
The Health Resources and Services Administration (HRSA) issued a request for information on reviving a 340B drug‑rebate model after a court‑blocked rollout. Hospital groups, led by the American Hospital Association, warn the model could impose over $1 billion in annual costs,...
New Blood-Based Method Identifies Testicular Cancer Missed by Standard Tests
Mayo Clinic scientists unveiled a blood‑based assay, GCT‑iSIGN, that detects germ cell tumors with 93% sensitivity and 99% specificity, even when conventional tumor markers are negative. In a cohort of 427 samples, the test caught 23 of 24 cases missed...
Multiple Myeloma Sequencing Evolves With CAR T, MRD Insights: Sylvester Homsy, MD
At an Institute for Value‑Based Medicine event in Charlotte, Sylvester Homsy, MD highlighted how CAR‑T cell therapy and bispecific antibodies are reshaping multiple myeloma treatment sequencing. The emergence of B‑cell maturation antigen‑targeted agents is prompting clinicians to consider these high‑efficacy...
Cannabis Rescheduling: What Does It Mean for Your Intellectual Property
The U.S. Department of Justice has reclassified FDA‑approved and state‑licensed medical marijuana products to Schedule III under the Controlled Substances Act, following President Trump’s 2025 executive order. This shift removes the “unlawful use” barrier that previously blocked trademark protection for cannabis‑related...
US Pricing Reform Reshapes Drug Launch Strategies: Dee Chaudhary
U.S. drug‑pricing reforms, especially the Most Favored Nation (MFN) rule, are forcing manufacturers to align American prices with the lowest prices offered abroad. As a result, firms are pulling back from launches in France, Germany and the Nordic region to...
Scientists Uncover a Hidden Mechanism Cancer Cells Use to Rewrite Genetic Messages, Revealing a Promising New Target for Treatment
A team of molecular biologists has uncovered a previously unknown RNA‑binding protein that rewrites messenger‑RNA messages in cancer cells, effectively reprogramming gene expression. The discovery explains how tumors can rapidly adapt to hostile environments and develop resistance to standard chemotherapy....
WHO Designates Network of Regional Biomanufacturing Training Centers
The World Health Organization has officially designated a network of regional biomanufacturing training centers spanning all six WHO regions, marking a major step in building a skilled global workforce for vaccines, biotherapeutics and other biologics. The centers—located in Senegal, South...
How Price Transparency Could Fix the Abandoned Rx Issue: Laura Jensen
GoodRx’s chief commercial officer Laura Jensen argued that greater drug‑price transparency could dramatically cut the roughly one billion annual abandoned prescriptions in the United States. Speaking at Asembia’s AXS26 conference, she highlighted how transparent, consumer‑facing platforms can deliver easier‑to‑access discounts for...
New AI Models Quickly Find Compounds that Target Lyme Bacteria
Tufts University researchers have leveraged AI and machine‑learning to rapidly pinpoint narrow‑spectrum antibiotics that kill the Lyme disease bacterium Borrelia burgdorferi. Screening 60,000 existing compounds yielded several hundred hits, and generative models now explore an estimated 10^60 drug‑like molecules to...
Advanced Gene Editing ‘Promising’ for Sickle Cell Disease
Two recent New England Journal of Medicine studies demonstrate that CRISPR‑Cas12a (reni‑cel) and base‑editing (risto‑cel) autologous stem‑cell therapies can dramatically raise fetal hemoglobin and normalize total hemoglobin in sickle cell patients. The RUBY trial reported a rise from 2.5% to...
FDA Debuts Plan to Collect Real-Time Clinical Trial Data
The U.S. Food and Drug Administration announced a pilot program that will collect clinical‑trial data in real time, allowing scientific reviewers to see information as it is generated. The initiative, launched on Tuesday, includes participation from major drugmakers AstraZeneca and...
GLP-1 Receptor Agonist Add-On at Immune Checkpoint Inhibitor Initiation and Fewer Wasting-Related Diagnoses and Acute-Care Episodes in People with Cancer...
A target‑trial emulation of US TriNetX data examined cancer patients with obesity who started immune checkpoint inhibitors (ICIs) and received a GLP‑1 receptor agonist (GLP‑1 RA) at initiation. After 1:1 propensity matching, 988 patients per arm were followed for up to...
Pfizer Delays Patent Cliff for Blockbuster Vyndamax
Pfizer announced a two‑year extension of market exclusivity for Vyndamax (tafamidis), pushing the expected generic launch to 2026. The extension stems from a new formulation patent and a pediatric study that grant additional protection. Vyndamax, approved for transthyretin amyloid cardiomyopathy,...
Dual-Agonist Survodutide Shows Significant Weight Loss in Phase III Obesity Trial
Boehringer Ingelheim reported that its dual glucagon/GLP‑1 agonist survodutide produced up to 16.6% average weight loss after 76 weeks in the Phase III SYNCHRONIZE‑1 trial. The study also showed that 85.1% of treated participants achieved at least a 5% reduction, with...
Hikma and Amarin's Generic Drug Case Heads to Supreme Court Arguments
The U.S. Supreme Court will hear arguments this week in the dispute between Hikma Pharmaceuticals and Amarin over a prescription‑strength fish‑oil pill, the first generic challenge to Amarin’s Vascepa. The case centers on whether the FDA’s bioequivalence standards and the...
BIOTECanada Responds to Health Canada’s Gazette on a Draft Order Providing for Reliance on International Regulatory Authorities
Health Canada’s Gazette released a draft Order that would allow Canadian regulators to rely on approvals from trusted foreign agencies, a key component of the Red Tape Review initiative. BIOTECanada praised the proposal, calling it a meaningful step toward faster...
FDA Grants RMAT Status to Orca-Q in High-Risk Hematologic Malignancies
The U.S. Food and Drug Administration has awarded Regenerative Medicine Advanced Therapy (RMAT) designation to Orca‑Q, an investigational allogeneic T‑cell immunotherapy targeting high‑risk hematologic malignancies. The designation follows early phase 1 data that hint at improved overall survival, lower graft‑versus‑host disease...
Pfizer Deals Extend Patent Life for a Top-Selling Rare Disease Drug
Pfizer announced settlements with Dexcel Pharma, Hikma Pharmaceuticals and Cipla that push the patent expiry of its rare‑disease drug Vyndamax to June 1, 2031. The deals delay generic tafamidis entry, keeping U.S. sales stable through the early 2030s after the company warned...
Restylane, Sculptra Combo Improves Skin Dryness, Collagen Loss for Menopausal Women
Interim data from two investigator‑initiated trials show that a sequential regimen of Restylane Skinboosters followed by Sculptra markedly improves skin hydration, firmness and collagen density in menopausal women. The 9‑month study reported peak patient satisfaction at month six, with measurable...
Scientists May Have Finally Created a Male Birth Control Pill—So Far, It Shows Very Few Side Effects
YourChoice Therapeutics reported that its experimental male contraceptive pill YCT‑529 was well‑tolerated in a Phase 1 trial of 16 healthy, vasectomized men. The non‑hormonal compound halted sperm production without altering testosterone, heart rate, mood, or sexual desire. Pre‑clinical work in mice...
STAT+: Supreme Court to Hear Case About ‘Skinny Labeling’ and Generic Access
The U.S. Supreme Court will hear oral arguments on a case involving “skinny labeling,” a practice where generic manufacturers seek approval to market a drug for only a subset of its approved uses. By limiting the label, generics aim to...
$739 Million Acquisition of XOMA Strengthens Ligand’s Biopharma Portfolio
Ligand Pharmaceuticals announced a $739 million acquisition of XOMA Royalty, expanding its royalty‑financing portfolio to over 200 assets. The deal adds more than 120 new royalty streams, including seven marketed drugs such as Vabysmo and Ojemda, and deepens exposure to oncology,...
Rocket's PRV Goes for $180M; Oruka Targets $500M Offering
New Jersey‑based Rocket Pharmaceuticals sold its pediatric‑disease priority‑review voucher for $180 million, setting a near‑record price for such assets. The cash infusion strengthens Rocket’s balance sheet as it advances late‑stage gene‑therapy candidates. Meanwhile, biotech firm Oruka Therapeutics announced plans to raise...
Science in Space
NASA astronaut Chris Williams and ESA astronaut Sophie Adenot conducted the DNA Nano Therapeutics‑3 experiment in the Kibo laboratory’s Life Science Glovebox aboard the International Space Station. The study explores DNA‑inspired assembly techniques to fabricate nanostructured cancer therapies such as chemotherapy and...
BeOne Medicines Licenses Trispecific Antibody Targeting PD-1, CTLA-4 and VEGF
BeOne Medicines, the rebranded former BeiGene, announced a licensing and option agreement to acquire a trispecific antibody that simultaneously targets PD‑1, CTLA‑4, and VEGF. The experimental biologic originates from a Chinese biotech and is positioned for development in solid‑tumor indications....
Boehringer, Zealand’s Obesity Drug ‘More Akin’ to Novo’s Wegovy in Phase 3
Boehringer Ingelheim and Zealand Pharma reported that their glucagon/GLP‑1 dual agonist survodutide achieved a 13.4% (39.2 lb) average weight loss after 76 weeks in the Phase 3 SYNCHRONIZE‑1 trial, meeting primary endpoints and reducing waist circumference. Analysts compared the outcome to Novo...
AACR 2026: Combo Therapies by Moderna, Marengo Show Promise in Skin, Breast Cancer
Combination regimens dominated AACR 2026, with biotech firms showcasing new cocktail data across multiple tumor types. Marengo Therapeutics reported that its dual‑T‑cell agonist invikafusp alfa combined with Gilead’s ADC Trodelvy produced complete or partial responses in 40% of heavily pretreated...
Executing Biologics Technology Transfer Through Integrated Operating Models
The article advocates replacing the traditional sequential biologics tech‑transfer model with an integrated operating model that colocates development, manufacturing, MSAT and quality teams. By running small‑scale experiments and large‑scale runs concurrently, organizations can observe scale‑dependent effects in real time and...
Milestone for Crispr: First-of-Its-Kind Gene Editing Treatment Successfully Passes Clinical Trial
Intellia Therapeutics announced that its CRISPR‑based, one‑time gene‑editing therapy Lonzo‑z cleared a Phase 3 trial for hereditary angioedema, cutting swelling attacks by 87%. The double‑blind, placebo‑controlled study treated 52 of 80 patients and left 62% attack‑free without ongoing medication. Results represent...
STAT+: Boehringer’s Obesity Drug Shows 16.6% Weight Loss; More Data Needed
Boehringer Ingelheim reported that its experimental obesity drug produced an average 16.6% weight loss in a mid‑stage trial, signaling strong efficacy against a disease affecting over 100 million Americans. The study involved roughly 300 participants over 68 weeks and showed improvements...
Probiotic Candidate Shows Potential to Suppress UTIs
Researchers reported that the probiotic strain Limosilactobacillus reuteri 3613‑1, which produces the antimicrobial compound reuterin, can inhibit key urinary and vaginal pathogens. In a randomized, double‑blind, placebo‑controlled trial of 130 healthy women taking the probiotic daily for 24 weeks, the...
Erasca Plummets Despite 'Phenomenal' Results In Pancreatic Cancer
Erasca (ERAS) shares tumbled more than 45% to $10.50 after a patient in its pancreatic cancer trial died from pneumonia, a known side effect of the RAS‑blocking drug class. The death occurred when the patient withdrew from supportive care, despite...
Updated: AbbVie Flirts with Popular Pan-RAS Field in up to $1.45B Option to Acquire Kestrel
AbbVie has signed a deal giving it an option to acquire Kestrel Therapeutics for up to $1.45 billion, targeting Kestrel’s pan‑RAS inhibitor platform. The agreement includes an upfront payment and milestone‑based earn‑outs tied to regulatory and commercial milestones. Kestrel’s lead candidate,...
FDA Claims Trial 'Manipulation' Tainted Approval of ChemoCentryx Drug
The FDA has accused ChemoCentryx of manipulating key efficacy data in the pivotal Phase III trial that secured approval for its rheumatoid‑arthritis drug Tavneos. The agency says the new information renders the trial "tainted" and is moving to pull the treatment...
The US FDA Grants Priority Review and Breakthrough Therapy Designation to GSK’s Bepirovirsen for Chronic Hepatitis B
The U.S. FDA has accepted GSK’s new drug application for bepirovirsen, granting both priority review and breakthrough therapy designation for chronic hepatitis B. The decision is based on Phase III B‑Well 1 and B‑Well 2 trials across 29 countries, which showed higher functional‑cure...
U.S. Medical Centers Need a New Model for Drug Discovery and Development
For more than half a century U.S. academic medical centers (AMCs) have supplied the majority of FDA‑approved drug patents, but China’s rapid R&D expansion threatens that dominance. Chinese biotech now leads in novel medicine approvals and offers clinical trials that...
As Biosimilars Gain US Traction, Patent Thickets Are Under More Scrutiny
Sun Pharma announced a $12 billion acquisition of Organon to accelerate its entry into the global biosimilar market. The FDA has now approved roughly 90 biosimilars, which account for about 23 % of the U.S. biologics market, reflecting growing competition. Patent thickets—large...
Precision Radiation Therapy Could Offer New Hope For Hard-To-Treat Cancers
Radionuclide therapy, a precision cancer treatment delivering radioactive atoms directly to tumors, is gaining regulatory approvals and market traction. The class, anchored by early successes like Xofigo and the FDA‑approved Pluvicto, is projected to reach a $10.7 billion market by 2030....
GSK Eyes October FDA Verdict on Chronic Hep B Drug
GlaxoSmithKline’s antisense drug bepirovirsen entered an accelerated FDA review, with a decision expected by October 26. The phase‑2 B‑WELL 1 and B‑WELL 2 trials showed a statistically higher functional cure rate versus placebo when added to standard hepatitis B therapy. If approved, bepirovirsen would...
Novartis’ Sales Dip as Generics Pressure Intensifies, Radioequivalents Loom
Novartias first‑quarter net sales slipped 5% to $13.11 billion, primarily due to U.S. generic erosion of its heart‑failure drug Entresto. While earnings per share fell 11% to $1.65, growth was buoyed by double‑digit gains in Kisqali, Kesimpta and the radiopharma Pluvicto....